Corient Private Wealth
TNGX icon

Corient Private Wealth’s Tango Therapeutics TNGX Stock Holding History

Corient Private Wealth’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,058
Closed -$187K – 3025
2025
Q4 		$187K Buy
21,058
+9,558
+83% +$82.4K ﹤0.01% 2603
2025
Q3 		$96.6K Buy
+11,500
New +$77.8K ﹤0.01% 2455

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Corient Private Wealth's TNGX Position: Q1 2026 in Review

Corient Private Wealth sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 21,058 shares — an estimated $187K sold.

Corient Private Wealth first reported a position in TNGX in Q3 2025 and held it in 2 quarters. The position peaked at $187K in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Corient Private Wealth reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Corient Private Wealth sold 21,058 Tango Therapeutics shares in Q1 2026, an estimated $187K.
  • Corient Private Wealth first reported a position in Tango Therapeutics in Q3 2025 and held it in 2 quarters.
  • Corient Private Wealth's Tango Therapeutics position peaked at $187K in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.